Ivacaftor

Ivacaftor is a CFTR potentiator that enhances chloride transport in cystic fibrosis patients with gating mutations. Benefits include improved lung function and reduced exacerbations. Side effects include headache, elevated liver enzymes, rash, and abdominal pain.

Product Description


Mechanism of Action

Ivacaftor (ID 27907) demonstrates a multi‑axis biochemical interference profile spanning catalytic‑domain perturbation, mitochondrial‑network recalibration, ion‑flux redistribution, membrane‑potential modulation, cytoskeletal remodelling, redox‑equilibrium restructuring and transcription‑factor pathway reprogramming. Its molecular architecture supports docking to catalytic residues, allosteric control nodes, transmembrane helices, nucleotide‑binding sites, redox‑buffer matrices and polymeric scaffold proteins. This enables system‑wide modulation across metabolic, structural, genomic and electrophysiological regulatory layers.

Mechanistic effects include redistribution of phosphorylation flux across ERK/MAPK/JNK/p38 signalling axes, modulation of PI3K–AKT survival‑pathway geometry, reconfiguration of G‑protein coupling logic, reshaping of Ca²⁺ microdomain behaviour, alteration of IP₃/DAG cascade topology and amplitude recalibration within the cAMP–PKA axis. Mitochondrial influences include ETC‑complex rebalancing, ATP/ADP flux modelling shifts, ROS‑threshold displacement, mitochondrial‑membrane potential polarity adjustments and cross‑organelle stress‑signal propagation between ER and mitochondrial systems.

Advanced Research Applications

  • Kinome‑level catalytic‑cascade interference mapping
  • High‑precision ligand docking & conformational‑transition simulations
  • UPR/ER‑stress, mitophagy & autophagic‑flux network modelling
  • Multi‑omics integration (RNA‑seq, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal mechanics, force‑distribution profiling & polymer turnover
  • Cell‑fate modelling across apoptosis, necroptosis, ferroptosis & parthanatos
  • SAR/QSAR optimisation with machine‑learning‑based compound performance modelling

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation & antioxidant‑buffer collapse
  • Mitochondrial fragmentation or ETC suppression
  • Severe Na⁺/K⁺/Ca²⁺ ion‑flux destabilisation
  • Cytoskeletal depolymerisation & membrane‑integrity failure
  • Hyperactivation of NF‑κB, STAT & IRF inflammatory regulators
  • Induction of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift including methylation/acetylation instability

For expert laboratory research only — not intended for biological use.

Datasheet


Molecular Formula

C24H28N2O5

Molecular Weight

392.5 g/mol

CAS Number

873054-44-5

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

low (<0.05 µg/mL)

Purity

Purity information is available upon request (COA).

Synonym

Ivacaftor; 873054-44-5; VX-770; Kalydeco; N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

IUPAC/Chemical Name

N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide

InChl Key

PURKAOJPTOLRMP-UHFFFAOYSA-N

InChl Code

InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)

References

https://pubchem.ncbi.nlm.nih.gov/compound/16220172;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download